These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 15111758)

  • 1. Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy.
    Bodini M; Berruti A; Bottini A; Allevi G; Fiorentino C; Brizzi MP; Bersiga A; Generali D; Volpi D; Marini U; Aguggini S; Tampellini M; Alquati P; Olivetti L; Dogliotti L
    Breast Cancer Res Treat; 2004 Jun; 85(3):211-8. PubMed ID: 15111758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy.
    Schott AF; Roubidoux MA; Helvie MA; Hayes DF; Kleer CG; Newman LA; Pierce LJ; Griffith KA; Murray S; Hunt KA; Paramagul C; Baker LH
    Breast Cancer Res Treat; 2005 Aug; 92(3):231-8. PubMed ID: 16155794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal assessment of residual disease after neo-adjuvant therapy for locally advanced and inflammatory breast cancer--clinical examination, mammography, or magnetic resonance imaging?
    Wright FC; Zubovits J; Gardner S; Fitzgerald B; Clemons M; Quan ML; Causer P
    J Surg Oncol; 2010 Jun; 101(7):604-10. PubMed ID: 20461768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy.
    Chen X; Moore MO; Lehman CD; Mankoff DA; Lawton TJ; Peacock S; Schubert EK; Livingston RB
    Acad Radiol; 2004 Oct; 11(10):1115-24. PubMed ID: 15530804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer.
    Guarneri V; Pecchi A; Piacentini F; Barbieri E; Dieci MV; Ficarra G; Tazzioli G; Frassoldati A; Battista R; Canossi B; Mauri C; D'Amico R; Conte P; Torricelli P
    Ann Surg Oncol; 2011 Aug; 18(8):2150-7. PubMed ID: 21301969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy.
    Partridge SC; Gibbs JE; Lu Y; Esserman LJ; Sudilovsky D; Hylton NM
    AJR Am J Roentgenol; 2002 Nov; 179(5):1193-9. PubMed ID: 12388497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preoperative evaluation of pathologic response in patients with breast cancer by dynamic contrast-enhanced magnetic resonance imaging].
    Zhang XP; Li J; Sun YS; Cao K; Tang L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Feb; 30(1):98-103. PubMed ID: 18361063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
    Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
    Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy.
    Rosen EL; Blackwell KL; Baker JA; Soo MS; Bentley RC; Yu D; Samulski TV; Dewhirst MW
    AJR Am J Roentgenol; 2003 Nov; 181(5):1275-82. PubMed ID: 14573420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computer-aided detection applied to breast MRI: assessment of CAD-generated enhancement and tumor sizes in breast cancers before and after neoadjuvant chemotherapy.
    Demartini WB; Lehman CD; Peacock S; Russell MT
    Acad Radiol; 2005 Jul; 12(7):806-14. PubMed ID: 16039534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial.
    Bottini A; Berruti A; Brizzi MP; Bersiga A; Generali D; Allevi G; Aguggini S; Bolsi G; Bonardi S; Tondelli B; Vana F; Tampellini M; Alquati P; Dogliotti L
    Endocr Relat Cancer; 2005 Jun; 12(2):383-92. PubMed ID: 15947110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [MRI evaluation of primary chemotherapy response in breast cancer].
    Vénat-Bouvet L; Desfougères M; Aubard Y; Mollard J; Fermeaux V; Genet D; Labourey JL; Martin J; Lebrun-Ly V; Maubon A; Tubiana-Mathieu N
    Bull Cancer; 2004 Sep; 91(9):721-8. PubMed ID: 15544998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast conservation after induction chemotherapy for locally advanced breast cancer.
    Kling KM; Ostrzega N; Schmit P
    Am Surg; 1997 Oct; 63(10):861-4. PubMed ID: 9322658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI and conservative treatment of locally advanced breast cancer.
    Julius T; Kemp SE; Kneeshaw PJ; Chaturvedi A; Drew PJ; Turnbull LW
    Eur J Surg Oncol; 2005 Dec; 31(10):1129-34. PubMed ID: 15905068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients.
    Croshaw R; Shapiro-Wright H; Svensson E; Erb K; Julian T
    Ann Surg Oncol; 2011 Oct; 18(11):3160-3. PubMed ID: 21947594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-agent epirubicin as primary chemotherapy in T2-T3, N0-N2, M0 breast carcinoma: 6-year follow-up.
    Barni S; Piazza E; Frontini L; Visini M; Ardizzoia A; Grassi MM; Nosenzo MA; Mandalà M; Biasioli R; Freddi E; Lucani L; Recalcati A; Pravettoni A; Sala R; Rezzani C; Villa S; Trabucchi E;
    Oncology; 2004; 67(1):40-7. PubMed ID: 15459494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic enhanced MRI predicts chemosensitivity in breast cancer patients.
    Nagashima T; Sakakibara M; Nakamura R; Arai M; Kadowaki M; Kazama T; Nakatani Y; Koda K; Miyazaki M
    Eur J Radiol; 2006 Nov; 60(2):270-4. PubMed ID: 16926079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance imaging evaluation of residual ductal carcinoma in situ following preoperative chemotherapy in breast cancer patients.
    Choi HK; Cho N; Moon WK; Im SA; Han W; Noh DY
    Eur J Radiol; 2012 Apr; 81(4):737-43. PubMed ID: 21300498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.